Company intelligence / Profile preview

BARD1 Life Sciences

Notting Hill, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

BARD1 Life Sciences has commercialized assays for bladder cancer and exosome research, and its BARD1 and SubB2M assays have shown high sensitivity and specificity (>95% sensitivity, 100% specificity) in proof-of-concept results for breast and ovarian cancer. The company is working to expand to other common solid tumors, with strong clinical data in early-stage detection[1][7].

Therapeutic areas: Oncology
Modalities: Diagnostic assayELISAAutoantibody diagnostic testExosome capture tool
Industry: Protein Biomarker Diagnostics

Partnerships

Institute for Respiratory Health (academic)commercial partnerships with clinical laboratories and diagnostics distributors for go-to-market

Beyond the preview

Go deeper on BARD1 Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BARD1 Life Sciences.

Explore the full profile